Postcoital Testing of the SILCS Diaphragm
A Phase I Postcoital Testing and Safety Study of the SILCS Diaphragm, Prototype VI
This was a Phase I multi-center, randomized study in 40 healthy, sexually active women not at risk for pregnancy due to previous female sterilization. The male partners of the participants were consented to participate in the study. The clinician evaluating the cervical mucus for midcycle characteristics and presence of sperm was blinded as to gel used. The product tested was the SILCS diaphragm with Gynol II (spermicide) and the SILCS diaphragm with KY Jelly (lubricant). The sequence of diaphragm and gel use was determined by randomization. The study was conducted at two centers, Magee-Womens Hospital in Pittsburgh, Pennsylvania and CONRAD's Clinical Research Center at the Eastern Virginia Medical School in Norfolk, Virginia.
The study consisted of a screening visit, a baseline cycle, and up to 2 cycles of post-coital tests (PCTs) for a total of 7 visits. The first PCT was a baseline PCT, performed without the use of any product, in order to demonstrate the subject's ability to produce receptive, midcycle cervical mucus. The partner's ability to produce motile sperm capable of penetrating the cervical mucus was evaluated in this cycle. Test PCTs were carried out during the second and third menstrual cycle using either the SILCS diaphragm with N-9 or the SILCS diaphragm with lubricant. Cycles were repeated depending on the characteristics of the cervical mucus and the number of sperm found in the vaginal pool and endocervical specimens; thus, some women may undergo more than three PCTs. An additional test cycle with a modified polymer spring device was performed in a subset of participants.
Colposcopy was performed during the mucus check and post-coital test visits in all three cycles in order to document the baseline condition of the vagina and cervix pre- and post-intercourse and, in test cycles, to note the effect of product.
Vaginal samples were taken from the posterior fornix of the vagina and the cervical os at each visit during the baseline and test cycles to measure for the presence of PSA.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 1
Kontakter og lokationer
Studiesteder
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Forenede Stater, 15213
- University of Pittsburgh Medical Center
-
-
Virginia
-
Norfolk, Virginia, Forenede Stater, 23507
- Eastern Virginia Medical School
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
Female Participants
- 18-45 years old (inclusive)
- In good general health based on medical history & physical exam
- Previous bilateral tubal ligation or salpingectomy
- Regular menstrual cycles of 24-35 days (inclusive)
- Negative urine pregnancy test at admission
- Not currently breast feeding
- No significant gynecological abnormalities
- Normal cervical Papanicolaou smear within 6 months preceding enrollment
- In a stable relationship with only one sexual partner
- Willing to undergo at least three PCTs
- Willing to abstain from intercourse and use of vaginal products
- Willing to use condoms from day 1 of each menstrual cycle until midcycle
Male Participants
- Age 18 years and older
- Able and willing to provide written informed consent
- Willing to engage in intercourse with and without condoms
Exclusion Criteria:
Female Participants
- History in subject of allergy to study products
- Positive wet mount for Trichomonas vaginalis
- History of any STD within 6 months of enrollment
- Device does not appropriately fit volunteer, as determined by clinician
- Inability to insert, position, and/or remove study device
- Participation in another study within 30 days prior to enrollment
Male Participants
- History of allergy to study products
- History of vasectomy
- In the six months prior to study, diagnosed with or treated for any STI
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Crossover opgave
- Maskning: Enkelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Placebo komparator: 1
SILCS with K-Y Jelly
|
|
|
Aktiv komparator: 2
SILCS with N-9
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Percentage of women with any sperm in the cervical mucus, with ≥ 5 progressively motile sperm per high power field (HPF), and the average number of progressively motile sperm per HPF.
Tidsramme: Within 2-3 hours of intercourse.
|
Within 2-3 hours of intercourse.
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Symptoms and signs of irritation of the external genitalia, cervix, and vagina before and after intercourse and by gel product. The handling, fit, and general acceptability of the SILCS diaphragm was assessed.
Tidsramme: Before and after intercourse
|
Before and after intercourse
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Studieleder: Jill Schwartz, MD, CONRAD
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- A02-081
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .